Pharsight

Clindesse generic

Clindesse is an anti-bacterial drug owned by Padagis Us. It contains the active ingredient clindamycin phosphate and was authorized for market use on 30 November, 2004. The drug has a total of 2 patents, one of which has already expired.

When will Clindesse generic be available?

The generics of Clindesse are expected to be available after 02 December, 2026. This availability is based on the expiration date of the last patent, US9789057, titled as 'Pharmaceutical delivery system'. Please note that availability may be sooner if a drug company is successful in a Paragraph IV patent litigation.

Clindesse uses

Containing clindamycin phosphate, Clindesse is primarily used for the treatment of bacterial vaginosis. It is available in the form of a vaginal cream.

Clindesse patent expiration

Regarding Clindesse patents, it initially had two patents. The first one, US6899890 titled as 'Bioadhesive drug delivery system', has already expired on 2023-04-27. The remaining patent, US9789057 titled as 'Pharmaceutical delivery system', is expected to expire on 2026-12-02. As a result, Clindesse generic is likely to be released post this date. Below are the details of the patent:

Litigations filed on Clindesse

Clindesse dosage

Want to ask something?